Friday, August 23, 2024 As the world continues to navigate the long-term effects of the COVID-19 pandemic, another public health challenge is threatening to disrupt the global travel industry: Mpox. Previously known as monkeypox, Mpox is a viral disease that has recently caught the attention of global health authorities due to an uptick in cases worldwide. In response, many countries have introduced stringent Mpox screening protocols at major international airports to prevent the virus from spreading across borders, a move that is poised to significantly impact the global tourism sector.
Mpox, a viral disease originally found in Central and West Africa, has increasingly been reported in various parts of the world, including Europe, North America, and Asia. The disease is caused by the Mpox virus, which shares similarities with the smallpox virus, though Mpox is generally less severe. Symptoms of Mpox include fever, rash, and swollen lymph nodes, with severe cases posing a particular threat to immunocompromised individuals.
Historically, Mpox outbreaks were largely confined to remote regions of Africa, with limited international impact. However, recent years have seen a significant shift, with cases being reported in countries far removed from the virus’s original endemic regions. This shift has been attributed to several factors, including increased global travel, environmental changes, and the interconnectivity of modern society.
The global health community has expressed s.